Calliditas Therapeutics

Renal/hepatic disease therapeutics

Subsidiary of Asahi Kasei Corporation (3407) · Sweden

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
IgA Nephropathy

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 July 2024Topline resultGKT137831Phase 2b TRANSFORM of setanaxib in PBC met its primary endpoint (ALP reduction versus placebo)
Calliditas Therapeutics AB · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$52M$11M$75M$4.4Mreport ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q2$26M$8.4M$80M$8.7Mreport ↗
2022-Q2$6.5M$9.8M$83M$20Mreport ↗
2022-Q1$5.3M$12M$88M$22Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$114M$47M$97M$11Mreport ↗

Calliditas Therapeutics reported revenue of $113.83M, up 43.1% YoY, R&D spend of $47.37M, up 15.3% YoY, cash and equivalents of $96.52M, and a net loss of $43.97M for fiscal year 2023.

Figures only: this period's report disclosed no narrative text

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2022-FY$80M$41M$120M$10Mreport ↗
2021-FY$27M$42M$106M$15Mreport ↗